1365-2141/asset/olbannerleft.gif?v=1&s=2237887a0dba115836e329b1c5824f93749b814b)
1365-2141/asset/olbannerright.gif?v=1&s=01b5795d608a5571b530fcd8eb300f01b48de3b2)
Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis
Article first published online: 2 OCT 2003
DOI: 10.1046/j.1365-2141.1996.5061047.x
1365-2141/asset/cover.gif?v=1&s=340532f3ee73ba9171e38abd4d7f6a926d117661 "British Journal of Haematology")
Additional Information
How to Cite
Bible, K. C. and Tefferi, A. (1996), Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. British Journal of Haematology, 93: 406–408. doi: 10.1046/j.1365-2141.1996.5061047.x
Publication History
- Issue published online: 2 OCT 2003
- Article first published online: 2 OCT 2003
- Abstract
- Cited By
Keywords:
- large granular lymphocytic leukaemia;
- natural killer cell lymphocytosis;
- cyclosporine A;
- severe anaemia;
- treatment
Large granular lymphocytic (LGL) leukaemia and chronic natural killer cell lymphocytosis (CNKL) are chronic indolent disorders often associated with neutropenia and constitutional symptoms. Severe anaemia occurs in about 20% of patients and is currently treated with corticosteroids followed by oral cyclophosphamide in non-responders. 30% of patients fail initial measures, and salvage therapy is inadequate. We describe three transfusion-dependent patients (two with T-LGL leukaemia, one with CNKL) refractory to corticosteroids, cyclophosphamide, and in one case fludarabine. Cyclosporine A (CSA) initiation resulted in prompt transfusion-independence and was well tolerated in all patients, making it an attractive alternative therapy for this disorder.